CXCL13 predicts disease activity in early rheumatoid arthritis and could be an indicator of the therapeutic `window of opportunity'
Stinne Ravn Greisen(Aarhus University), Malene Hvid(Aarhus University), Peter Junker(Odense University Hospital), Kristian Stengaard‐Pedersen(Aarhus University Hospital), Kim Hørslev‐Petersen(University of Southern Denmark), Merete Lund Hetland(University of Copenhagen), Tue Wenzel Kragstrup(Aarhus University), Mikkel Østergaard(University of Copenhagen), Bent Deleuran(Aarhus University), Tue Kruse Rasmussen(Aarhus University), Karen Kræmmer Schelde(Aarhus University)
Cited by 81
Related Papers
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis
|Annals of the Rheumatic Diseases|2013|668
Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study
|Arthritis Research & Therapy|2008|472